Cargando…
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial( )
AIMS: In a retrospective analysis of dal-Outcomes, the effect of dalcetrapib on cardiovascular events was influenced by an adenylate cyclase type 9 (ADCY9) gene polymorphism. The dal-GenE study was conducted to test this pharmacogenetic hypothesis. METHODS AND RESULTS: dal-GenE was a double-blind tr...
Autores principales: | Tardif, Jean Claude, Pfeffer, Marc A, Kouz, Simon, Koenig, Wolfgang, Maggioni, Aldo P, McMurray, John J V, Mooser, Vincent, Waters, David D, Grégoire, Jean C, L’Allier, Philippe L, Wouter Jukema, J, White, Harvey D., Heinonen, Therese, Black, Donald M, Laghrissi-Thode, Fouzia, Levesque, Sylvie, Guertin, Marie Claude, Dubé, Marie Pierre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565632/ https://www.ncbi.nlm.nih.gov/pubmed/35856777 http://dx.doi.org/10.1093/eurheartj/ehac374 |
Ejemplares similares
-
Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
por: Bouabdallaoui, Nadia, et al.
Publicado: (2020) -
Inhibition of the 3CL Protease and SARS-CoV-2
Replication by Dalcetrapib
por: Niesor, Eric J, et al.
Publicado: (2021) -
Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes
por: Tardif, Jean-Claude, et al.
Publicado: (2016) -
Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease
por: Schwartz, Gregory G., et al.
Publicado: (2020) -
The Adaptation of Temperate Bacteriophages to Their Host Genomes
por: Bobay, Louis-Marie, et al.
Publicado: (2013)